You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 122 No. 8, August 1987 TABLE OF CONTENTS
  Archives
  •  Online Features
  PAPERS READ BEFORE THE 13TH ANNUAL MEETING OF THE NEW ENGLAND SOCIETY FOR VASCULAR SURGERY DIXVILLE NOTCH, NH, SEPT 25 TO SEPT 26, 1986
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Effect of a Selective Thromboxane Synthase Inhibitor on Arterial Graft Patency and Platelet Deposition in Dogs

Martha D. McDaniel, MD; W. Thomas Huntsman, MD; Thomas O'C. Miett, MD; Jack L. Cronenwett, MD

Arch Surg. 1987;122(8):887-892.


Abstract

• This study examined the effect of selective thromboxane synthase inhibition and nonselective cyclooxygenase inhibition on vascular graft patency and indium 111–labeled platelet deposition in 35 mongrel dogs undergoing carotid artery replacement with 4 mm x 4 cm polytetrafluoroethylene (PTFE) (one side) and Dacron (opposite side) end-to-end grafts. Aspirin-dipyridamole therapy improved one-week graft patency, from 46% in untreated dogs to 93% in treated dogs. Thromboxane synthase inhibition (U-63557A) improved graft patency in these dogs to 81%. Both drug treatments reduced platelet deposition on Dacron and PTFE grafts by 48% to 68% compared with control dogs. Dacron grafts accumulated significantly more platelets than PTFE grafts but had comparable patency rates. Low-dose aspirin therapy had no significant effect on either graft patency or platelet deposition. All treatment groups showed a 60% to 76% reduction in serum thromboxane B2, but only thromboxane synthase inhibitor treatment increased plasma 6-keto-prostaglandin F1{alpha} by 100%. Selective thromboxane synthase inhibition improved small-caliber prosthetic graft patency to the same extent as did conventional cyclooxygenase inhibition in this preliminary study.

(Arch Surg 1987;122:887-892)



Author Affiliations

From the Section of Vascular Surgery, Dartmouth-Hitchcock Medical Center, Hanover, NH.


Footnotes

Accepted for publication May 26, 1987.

Read before the 13th Annual Meeting of the New England Society for Vascular Surgery, Dixville Notch, NH, Sept 25, 1986.

Reprint requests to Section of Vascular Surgery, Dartmouth-Hitchcock Medical Center, Hanover, NH 03756 (Dr McDaniel).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1987 American Medical Association. All Rights Reserved.